Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia

Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia

Optimizing olverembatinib dose in people with chronic phase chronic myeloid leukemia (CML) is important to increase safety without compromising efficacy. We designed a multi-center retrospective study comparing safety and efficacy of olverembatinib between the recommended dose of 40 mg every other...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoshuai Zhang, Yunfan Yang, Bingcheng Liu, Xin Du, Xiaodong Wang, Huanling Zhu, Lu Yu, Zongru Li, Shasha Zhao, Linhua Yang, Yanping Ma, Li Meng, Yanqing Zhang, Guohui Li, Lijie Yang, Baohong Wang, Xuehong Ran, Jian Huang, Na Gao, Qin Wen, Yan Wen, Yuxia Zhao, Yu Zhu, Yanqiu Han, Zhenfang Liu, Jianyu Weng, Robert Peter Gale, Li Zhou, Yanli Zhang, Qian Jiang
Format: Article
Language:English
Published: Ferrata Storti Foundation 2025-04-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/12047
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://haematologica.org/article/view/12047

Similar Items